U-Protein Express
MindWalk Holdings Corp. (NASDAQ: HYFT) is an AI-native biologics discovery company offering a BioIntelligence Ecosystem that combines its proprietary LensAI platform, the HYFT biological knowledge graph with 25B+ relationships, and advanced wet-lab research to serve pharmaceutical and biotechnology clients across antibody, peptide, and vaccine discovery programs.
- Company typePublic
- Founded2007
- HeadquartersUtrecht, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What U-Protein Express does
MindWalk Holdings Corp. (NASDAQ: HYFT), formerly ImmunoPrecise Antibodies, is a publicly traded biologics discovery company headquartered in the United States. The company operates a BioIntelligence Ecosystem that integrates three components: (1) Bio-Native LensAI, an AI platform powered by HYFT technology that links biological sequence, structure, function, and literature to produce explainable insights; (2) the HYFT knowledge graph, which structures more than 25 billion biological relationships across targets, sequences, and functions; and (3) advanced wet-lab research services including the proprietary B cell Select screening platform and Rapid Prime immunization method. The company serves pharmaceutical and biotechnology customers across antibody discovery, peptide therapeutics, vaccine programs, anti-drug antibody discovery, diagnostic antibody discovery, and protein engineering and production, reporting 20+ client molecules advanced to the clinic.
MindWalk operates a dual go-to-market. The 'We Build It' motion is a full-service enterprise engagement where dedicated scientific and technology experts work 1:1 with clients to adapt the platform to program needs; named customers include Acumen Pharmaceuticals, GentiBio, OncoResponse, and Amyl Therapeutics, with strategic partnerships with Janssen Pharma, Novo Nordisk, Argenx, Genmab, and the NIH. The 'You Build It' motion is the LensAI SaaS self-serve platform, enabling independent in silico screening, developability analysis, and protein engineering. Pricing is quote-based and not publicly disclosed, and revenue streams include biologics discovery services, SaaS subscriptions, and collaborative research partnerships. Recent product launches include ReefIQ (a Biological Context Layer for AI Drug Discovery, 2024) and LensAI SaaS, alongside deployment of HYFT as a pandemic response platform for Ebola and Hantavirus outbreaks.
U-Protein Express firmographics
Firmographics- Name
- U-Protein Express
- Legal name
- MindWalk Holdings Corp.
- Website
- https://www.u-proteinexpress.com/
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MindWalk Holdings Corp. (NASDAQ: HYFT) is an AI-native biologics discovery company offering a BioIntelligence Ecosystem that combines its proprietary LensAI platform, the HYFT biological knowledge graph with 25B+ relationships, and advanced wet-lab research to serve pharmaceutical and biotechnology clients across antibody, peptide, and vaccine discovery programs.
- Ownership category
- akta.pro rank
U-Protein Express industry classification
Industry- Product category
- Biologics Discovery Software & Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where U-Protein Express is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
U-Protein Express business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Biologics Discovery Services: Full-service discovery platform providing antibody discovery and development, therapeutic antibody programs, anti-drug antibody discovery, diagnostic antibody discovery, and protein engineering & production services to pharmaceutical and biotech companies.
- LensAI SaaS Platform: Self-serve AI-powered SaaS platform providing access to LensAI computational tools for in silico screening, developability analysis, and protein engineering.
- Collaborative Research Partnerships: Strategic partnerships and collaborative research arrangements with pharmaceutical companies for targeted drug discovery programs.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
U-Protein Express product offering
Product offeringCore offering
U-Protein Express operates a BioIntelligence Ecosystem integrating Bio-Native AI (LensAI), a biological knowledge graph (HYFT with 25+ billion relationships), and advanced wet lab research to provide antibody discovery and development, therapeutic antibody programs, anti-drug antibody discovery, diagnostic antibody discovery, and protein engineering and production services to pharmaceutical and biotech companies. The company also offers a self-serve LensAI SaaS platform for in silico screening, developability analysis, and protein engineering.
Product overview
MindWalk's BioIntelligence Ecosystem is a hybrid platform integrating Bio-Native AI, deep biological data, and advanced lab research. The core technology stack includes LensAI (AI-powered biological context platform), HYFT (biological knowledge graph with 25+ billion relationships), and B cell Select (antibody discovery platform). The ecosystem is configured for antibody discovery and development (therapeutic antibodies, anti-ID/anti-drug antibodies, diagnostics), peptide therapeutics, and vaccine programs. Self-service access is available via LensAI SaaS, while full-service programs include Advanced Lab Research integration. Additional offerings include ReefIQ (biological context layer) and The Vault (partner-ready biologics pipeline assets).
Differentiator
Problem solved
Functional benefit
Brands
- LensAI: Bio-Native AI platform powered by HYFT that links sequence, structure, function, and literature to generate deeper biological insight for molecular discovery.
- HYFT
- B cell Select
- ReefIQ
- LensAI SaaS
Quantifiable outcome
- 20+ client molecules advanced to clinical trials
- +2 more outcomes
Companies that use U-Protein Express
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles2 records
U-Protein Express technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
U-Protein Express partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major and core.
- ArgenxmajorCollaboration with Argenx on antibody discovery research. Published research in Nature Scientific Reports demonstrating successful application of MindWalk's technologies in therapeutic antibody development.
- GenmabmajorTechnology partnership targeting infectious disease with Genmab, leveraging MindWalk's discovery platform and LensAI capabilities.
- Janssen PharmamajorStrategic agreement with Janssen (Johnson & Johnson) for antibody discovery services, utilizing MindWalk's integrated discovery platform.
- NIH (National Institutes of Health)majorCollaboration with NIH and Integrated BioTherapeutics to study structural details of antibodies with therapeutic potential to treat or prevent COVID-19.
- Novo NordiskmajorResearch collaboration with Novo Nordisk published in EMBO Molecular Medicine, demonstrating platform capabilities in therapeutic antibody discovery.
- OncoResponsecorePartnership for development of immunoinhibitory receptor drug candidates using B cell Select platform. Candidates now in Phase I/II clinical trials.
- MJ Fox FoundationcoreResearch collaboration contributing to Parkinson's disease research, with findings published in scientific literature.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
U-Protein Express competitors and assessment
Company assessmentDirect peers
- AbCellera Biologics: Public antibody discovery platform combining proprietary screening technology with computational tools for pharma partners. Closely comparable to MindWalk in offering antibody discovery services with advanced wet-lab capabilities and emerging AI/ML integration.
- Adimab: Private antibody discovery and engineering CRO serving pharma and biotech with proprietary yeast-display platforms. Comparable to MindWalk's B cell Select and therapeutic antibody discovery services for similar pharma customer base.
- Schrödinger: Public computational drug discovery company combining physics-based modeling with AI for molecular design. Comparable to MindWalk's LensAI in silico screening and developability analysis capabilities, serving overlapping pharma R&D buyers.
- Generate Biomedicines: Well-funded AI protein design company (Flagship-backed) developing generative models for novel biologics. Most directly comparable to MindWalk's AI-enabled protein engineering and antibody discovery ambition.
- Isomorphic Labs: Alphabet-backed AI drug discovery company with major pharma partnerships focused on computational biology and protein structure prediction. Comparable to MindWalk's AI-first biologics discovery approach at a much larger capital scale.
Broad incumbents
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning at greater scale than MindWalk. Comparable as a broader AI drug discovery player though focused on internal pipeline rather than services.
- Insitro: AI-driven drug discovery company combining machine learning with biology data for pharma partnerships. Comparable as a platform competitor in AI-enabled biologics discovery serving large pharma partners.
- Charles River Laboratories: Large public CRO providing biologics discovery, safety assessment, and manufacturing services. Comparable as a broader discovery services incumbent though less AI-specialized than MindWalk.
Emerging players
- Twist Bioscience: Public synthetic biology and antibody discovery company offering discovery services and reagents. Comparable to MindWalk in antibody discovery offerings with overlapping customer base in pharma R&D.
- Cradle Bio: AI protein engineering company offering generative models for biologics design to pharma and biotech. Comparable emerging player in AI-enabled protein engineering with similar customer overlap to MindWalk.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
U-Protein Express social profiles
Digital presenceU-Protein Express financial estimates
Financial estimateRevenue estimate
Valuation estimate
U-Protein Express leadership team
Management profileNumber of profiles
U-Protein Express funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
U-Protein Express M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about U-Protein Express
What does U-Protein Express do?
U-Protein Express operates a BioIntelligence Ecosystem integrating Bio-Native AI (LensAI), a biological knowledge graph (HYFT with 25+ billion relationships), and advanced wet lab research to provide antibody discovery and development, therapeutic antibody programs, anti-drug antibody discovery, diagnostic antibody discovery, and protein engineering and production services to pharmaceutical and biotech companies. The company also offers a self-serve LensAI SaaS platform for in silico screening, developability analysis, and protein engineering.
Is U-Protein Express a public or private company?
U-Protein Express is a public company. It is classified as public and is currently operating.
When was U-Protein Express founded?
U-Protein Express was founded in 2007. It employs 11 to 50 people.
Where is U-Protein Express based?
U-Protein Express is headquartered in Utrecht, Netherlands, in the Europe region.
How does U-Protein Express make money?
Three revenue lines are on record. Biologics Discovery Services are the primary driver. The others are lensAI SaaS Platform and collaborative Research Partnerships.
Who are U-Protein Express's main competitors?
Direct peers on record are AbCellera Biologics, Adimab, Schrödinger, Generate Biomedicines and Isomorphic Labs. Broad incumbents are Recursion Pharmaceuticals, Insitro and Charles River Laboratories. Emerging players are Twist Bioscience and Cradle Bio.
Does U-Protein Express have an API?
No public API is recorded for U-Protein Express.
What industry is U-Protein Express in?
U-Protein Express's product category is Biologics Discovery Software & Services. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.